CLINICAL TRIALS PROFILE FOR JANTOVEN

All Clinical Trials for JANTOVEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02574754 ↗	Assessment of 2012 Bioequivalence Standards for Warfarin	Completed	University of California, San Francisco	Phase 1	2016-05-01	The purpose of this study is to assess the 2012 bioequivalence statistical criteria for warfarin, a narrow therapeutic index drug, set forth in the draft guidance issued by the Food and Drug Administration (FDA).
NCT02942407 ↗	Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation	Completed	Bristol-Myers Squibb	Phase 4	2016-12-01	This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .
NCT02942407 ↗	Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation	Completed	Christopher Granger	Phase 4	2016-12-01	This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .
NCT02942407 ↗	Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation	Completed	Christopher Granger, MD	Phase 4	2016-12-01	This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .
NCT02943785 ↗	Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)	Completed	Chiltern International Inc.	Phase 3	2017-03-21	When the upper chambers of a person's heart receive irregular electrical signals it causes abnormal rhythm in the heart beat. This is called atrial fibrillation. Atrial fibrillation increases the chance of having a heart attack or stroke. Some patients also get new heart valves using a catheter. Often doctors give patients a medicine called a vitamin K antagonist (VKA), because it is considered the standard care. This study will see how edoxaban compares to VKA in patients who got a new heart valve by using a catheter. The study will compare the two drugs for up to three years after heart valve replacement, looking at the drug's overall side effects (called adverse events) and major bleeding.

Clinical Trial Conditions for JANTOVEN

Condition Name

Condition Name for JANTOVEN
Intervention	Trials
Atrial Fibrillation	2
Atrial Fibrillation and Flutter	1
Drug Interaction Potential	1
End Stage Renal Disease	1

Condition MeSH

Condition MeSH for JANTOVEN
Intervention	Trials
Atrial Fibrillation	3
Kidney Failure, Chronic	2
Atrial Flutter	1

Clinical Trial Locations for JANTOVEN

Trials by Country

Trials by Country for JANTOVEN
Location	Trials
United States	71
Japan	12
Korea, Republic of	6
Spain	5
Canada	4

Trials by US State

Trials by US State for JANTOVEN
Location	Trials
California	4
Washington	3
Texas	3
New York	3
Michigan	3

Clinical Trial Progress for JANTOVEN

Clinical Trial Phase

Clinical Trial Phase for JANTOVEN
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 1	2

Clinical Trial Status

Clinical Trial Status for JANTOVEN
Clinical Trial Phase	Trials
Completed	4
Recruiting	1

Clinical Trial Sponsors for JANTOVEN

Sponsor Name

Sponsor Name for JANTOVEN
Sponsor	Trials
Daiichi Sankyo, Inc.	2
University of California, San Francisco	1
Bristol-Myers Squibb	1

Sponsor Type

Sponsor Type for JANTOVEN
Sponsor	Trials
Other	5
Industry	5